Ethnic sensitivity study of fingollimod in white and Asian subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 2, 2007, Pages 98-109

  Kovarik, John M ^a   Slade, A ^a   Voss, B ^a   Schmidli, H ^a   Riviere, G J ^a   Picard, F ^a   Sugita, Y ^a   Kawai, R ^a   Mee Lee, D ^b   Schmouder, R L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Hawaii Clinical Research Center   (United States)

Author keywords

Ethnicity; Fingolimod; Immunosuppressives

Indexed keywords

FINGOLIMOD; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 33847421937     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp45098     Document Type: Article

References (11)

1. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 2002; 14: 569-575.
2. Döring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life. 2004; 56: 615-620.
3. 5: Ethnic factors in the acceptability of foreign clinical data; 1998.
4. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit. 2004a; 26: 585-587.
5. Kovarik JM, Schmouder RL, Barilla D et al. Multiple-dose FTY720: tolerability, pharmacokinetics and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004b; 44: 532-537.
6. Kovarik JM, Schmouder RL, Barilla D et al. Single-dose FTY720 pharmacokinetics, food effect and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004c; 57: 586-591.
7. Kovarik JM, Schmouder RL, Serra D et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol. 2005; 45: 446-452.
8. Li H, Meno-Tetang GML, Chiba K et al. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2(4-octylphenyl)ethyl]propane-l,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther. 2002; 301: 519-526.
9. Schmouder RL, Barilla D, Wang Y et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006; 46: 895-904.
10. Smith BP, Vandenhende FR, DeSante KA et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000; 17: 1278-1283.
11. Tedesco-Silva H, Mourad G, Kahan BJ et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2005; 79: 1553-1560.